ARTICLE | Company News
FDA accepts Genzyme BLA
September 19, 2000 7:00 AM UTC
The FDA accepted for review GENZ's BLA for Fabrazyme agalsidase beta enzyme replacement therapy to treat Fabry's disease. The agency also approved GENZ's request for priority review. GENZ submitted th...